ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

KEY HIGHLIGHTS:

WESTON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2024, and provides business update.

Read more at globenewswire.com